Premier Biomedical(OTCQB:BIEI) is proud to have on
Post# of 41423
Posted On: 07/01/2016 11:51:28 AM
Premier Biomedical(OTCQB:BIEI) is proud to have on its Scientific Advisory Board, Ryan C. Fields, M.D., F.A.C.S.
After completing a Surgical Oncology Fellowship at Memorial Sloan-Kettring Cancer Center, Dr. Fields joined the faculty at Washington University. His clinical interests include the treatment of primary and secondary/metastatic liver tumors, pancreatic cancer, gastric cancer, sarcoma and melanoma/skin cancer. His research focuses on the biology and genetics of cancer metastases. Through collaborations with The McDonnell Genome Institute at Washington University and colleagues in the Department of Medical Oncology, Dr. Fields and his team are applying cutting edge genomic techniques to investigate the changes a tumor undergoes from primary malignancy to metastatic disease.
Learn more about the members of their Scientific Advisory Board: http://www.premierbiomedical.com/about/scient...ory-board/
Uptick Newswire provided the above as a paid service. It is understood that Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. Any suggestions made by Uptick Newswire staff regarding companies featured on upticknewswire.com is solely that “a suggestion” nothing more. It is our expectation that investors will do their own due diligence. We recommend that readers use the information found within as a starting point for conducting their own research on the featured company in order to determine their own personal opinion of the company before investing. Uptick Newswire is not liable for any investment decisions made by our readers. Readers should investigate and fully understand all risks before investing.
After completing a Surgical Oncology Fellowship at Memorial Sloan-Kettring Cancer Center, Dr. Fields joined the faculty at Washington University. His clinical interests include the treatment of primary and secondary/metastatic liver tumors, pancreatic cancer, gastric cancer, sarcoma and melanoma/skin cancer. His research focuses on the biology and genetics of cancer metastases. Through collaborations with The McDonnell Genome Institute at Washington University and colleagues in the Department of Medical Oncology, Dr. Fields and his team are applying cutting edge genomic techniques to investigate the changes a tumor undergoes from primary malignancy to metastatic disease.
Learn more about the members of their Scientific Advisory Board: http://www.premierbiomedical.com/about/scient...ory-board/
Uptick Newswire provided the above as a paid service. It is understood that Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. Any suggestions made by Uptick Newswire staff regarding companies featured on upticknewswire.com is solely that “a suggestion” nothing more. It is our expectation that investors will do their own due diligence. We recommend that readers use the information found within as a starting point for conducting their own research on the featured company in order to determine their own personal opinion of the company before investing. Uptick Newswire is not liable for any investment decisions made by our readers. Readers should investigate and fully understand all risks before investing.
(0)
(0)Scroll down for more posts ▼